Enhancing drug discovery and development
through quality analytical services

ABOUT RMI LABORATORIES

RMI Laboratories was founded in 2008 as a contract research organization whose goal is to enhance the drug discovery and development efforts of our clients by providing quality analytical services. RMI was founded by a leading team of professionals from the US pharmaceutical and contract services industries, and was started in response to the growing demand for high quality ADME services from small drug discovery companies without a state-of-the-art in-house bioanalytical facility.

Our mission is to be a leader in providing quality analytical services in the drug discovery and development arena by collaborating with our customers thus delivering the best solutions to their specific needs.

RMI’s approach is to provide data of the highest quality, rapidly and at a competitive price point.

Our facility is licensed by the DEA to handle scheduled drug substances and by the Pennsylvania DEP to handle 3H and 14C labeled material.

RMI Laboratories utilizes state-of-the-art mass spectrometry and ancillary instrumentation to support the services we provide.

Our management team has jointly 50+ years of mass spectrometry based experience in support of drug discovery and development. With almost 30 years’ experience in DMPK projects, we understand the challenges facing our clients in the work they conduct and are ideally suited to provide Merck PPDM a high quality, rapid and cost effective source for discovery ADME/DMPK support.

Executive Management Team

Executive Management Team

Sean Yu Ph.D.
CEO & Co-founder

Dr. Yu completed his doctoral studies at Rutgers University and joined Scientech Laboratories as Section Manager.

In 1995, he joined Merck Research Laboratories in the Department of Drug Metabolism and Pharmacokinetics, and worked on both drug discovery and development projects. He was involved in setting up a state of art mass spectrometry group and provided support to many drug development programs by providing high quality ADME data, particularly metabolite identification.

His final role at Merck was leading a team providing global metabolite ID support and was responsible for several innovative approaches which resulted in increased efficiency. He is viewed as one of industry leaders in terms of metabolite identification, and has many papers published in peer-reviewed journals.


Executive Management Team

Philip Tiller Ph.D.
Vice-President & Co-founder

Dr. Tiller obtained his Ph.D. from the Imperial College of Science, Technology and Medicine, University of London. His thesis work was on the structural elucidation of cell surface polysaccharides by mass spectrometry.

Subsequently he worked for VG Analytical and VG Biotech (now part of Waters) dealing with sector and quadrupole based instrumentation. He has also worked for Finnigan (part of Thermo) as the product manager for the LCQ and LCQ-DECA instruments.

Dr. Tiller has 15 years experience working in the Pharmaceutical industry initially at Glaxo in England and at Merck in the US.

His focus has been the application of mass spectrometry in solving analytical problems, in particular the application of HRMS in metabolite Identification.